Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New app aims to help cancer patients report side effects from home

NCT ID NCT04915274

Knowledge-focused Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a smartphone app called QuestOnco can reliably track side effects in 134 adult cancer patients receiving active treatment. Patients used the app to report symptoms, and researchers compared those reports to standard paper questionnaires. The goal was to see if the app is a valid and easy way for patients to communicate treatment side effects to their doctors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
QuestOnco mobile application
What this could lead to
If validated, this app could give doctors a reliable way to monitor cancer treatment side effects remotely, improving patient care.
What could go wrong
This is a small, completed validation study, not a treatment trial. The app may not work for all patients or may have technical issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

134 people

The number who actually took part.

Started

May 2021

Finished

Jan 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years); * Written and informed consent; * Diagnosis of solid cancer; * Metastatic or (neo)adjuvant anti-cancer treatment, including intravenous and/or oral treatments; * Patient physically/psychologically fit to participate in the study; * Patient able to understand, communicate and use the electronic device; * Patient owning a smartphone or tablet with internet connection; * Treatment supported by the French social security system. Exclusion Criteria: * Unable patient for signing informed consent; * Unable to understand, communicate and use the electronic device; * Patient under trusteeship or guardianship; * Patient under legal or administration protection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • Centre Régional Metz-Thionville

    Metz, 57085, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.